Press Releases

 
Press Releases
  Date Title and Summary View
Jun 19, 2003
PITTSBURGH--(BUSINESS WIRE)--June 19, 2003--Mylan Laboratories' (NYSE:MYL) brand subsidiary, Bertek Pharmaceuticals received an Untitled Letter from the United States Food and Drug Administration (FDA) regarding a certain specific reference on its Amnesteem® website. Having been made aware of th...
Jun 16, 2003
PITTSBURGH--(BUSINESS WIRE)--June 16, 2003--Mylan Laboratories Inc. (NYSE:MYL) announced today that the regular quarterly cash dividend of $0.0333 per share will be paid on July 15, 2003, to shareholders of record on June 30, 2003. Mylan Laboratories Inc. is a leading pharmaceutical company that develops, manufactures and markets gener...
Jun 2, 2003
PITTSBURGH, Jun 2, 2003 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) announced today that the U.S. Food and Drug Administration (FDA) has granted final approval for its Abbreviated New Drug Application (ANDA) for Omeprazole Delayed-release Capsules, 10 mg and 20 mg strengths and tentative approval for the 40 mg strength. O...
May 8, 2003
PITTSBURGH--(BUSINESS WIRE)--May 8, 2003--Mylan Laboratories Inc. (NYSE: MYL) Financial Highlights -- Record diluted earnings per share of $1.45 for fiscal 2003 and $.40 for the fourth quarter, compared to $1.36 and $.35, respectively, in the prior year. -- Net revenues increased by 15% to a record $1.27 b
Apr 28, 2003
CANONSBURG, Pa., Apr 28, 2003 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE: MYL) announced today that it will release its fourth quarter and fiscal 2003 financial results before the market opens on Thursday, May 8, 2003. Mylan management will host a conference call and live Webcast at 10:00 AM EDT to discuss the financial resul...
Apr 11, 2003
PITTSBURGH, Pa.--(BUSINESS WIRE)--April 11, 2003--Mylan Laboratories Inc. (NYSE:MYL) announced today that it has agreed to a tentative settlement under which it will receive $12.5 million from Aventis Pharmaceuticals, Inc. The Company also announced that it will receive an additional $10 million from its co-defendants in the lorazep...
Apr 10, 2003
PITTSBURGH, Pa.--(BUSINESS WIRE)--April 10, 2003--Mylan Laboratories Inc. (NYSE: MYL) a leading developer, manufacturer and marketer of generic and proprietary pharmaceuticals announced today the relocation of its Corporate Headquarters to a new state-of-the-art office complex in Canonsburg, Pennsylvania. The new offices, within the...
Apr 2, 2003
PITTSBURGH--(BUSINESS WIRE)--April 2, 2003--Mylan Laboratories Inc. (NYSE: MYL) announced today that it received confirmation from the FDA in February, 2003 that the Company's Modafinil (Provigil®) ANDA has been accepted for filing. The FDA accepted Mylan's application which contains a Paragraph ...
Apr 2, 2003
Apr 02, 2003 (BUSINESS WIRE) -- In BW 5131 (PA-MYLAN-LABORATORIES) Mylan Announces Filing of Modafinil ANDA, in the second graf, first sentence, read it xxx December 24, 2002 (sted xxx December 24, 2003). The full corrected sentence reads: The FDA accepted Mylan's application which contains a Paragraph IV certification...
Apr 1, 2003
PITTSBURGH--(BUSINESS WIRE)--April 1, 2003--Mylan Laboratories Inc. (NYSE:MYL) announced today that the U.S. Food and Drug Administration has approved its Abbreviated New Drug Application for Tizanidine Hydrochloride Tablets, 2mg and 4 mg. Tizanidine Hydrochloride is the generic version of Elan Corporation's Zanaflex...
Page: FirstPrevious ...
106
... NextLast
= add release to Briefcase